CLOs on the Move

Novozymes

www.novozymes.com

 
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow`s industrial biosolutions, improving our customers' business and the use of our planet`s resources.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.novozymes.com
  • 9000 Development Drive
    Morrisville, NC USA 27560
  • Phone: 919.494.3000

Executives

Name Title Contact Details

Similar Companies

Third Wave Technologies

Third Wave Technologies, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

3B Scientific

The international group of companies 3B Scientific specializes in the manufacturing and marketing of didactic material for scientific, medical and patient education. The group`s oldest site in Budapest/Hungary began its manufacturing history in 1819, making 3B Scientific the most experienced group of companies in the industry. The mother company was founded 1948 in Hamburg by the 3 Bs: Mr. Paul Binhold, his wife Hedwig Binhold and their daughter Marion Binhold, now Marion Kurland.

Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.

Expansion Therapeutics

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

ImmunityBio

ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.